CD19 and neoplasm: Rotolo et al. found that CD1d-restricted CD19-CAR-NKT cells outperformed CD19-CAR-T cells in targeting CD1d-positive lymphomas, achieving significant tumour reduction after a single dose without causing GVHD [174].